Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLAS-A/B fitusiran versus on-demand factor concentrate in hemophilia A or B without inhibitors
NL-OMON46599Phase 3Withdrawn
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Mar 2018
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fitusiran in hemophilia A and hemophilia B (HB) (2 arms), sponsored by Alnylam Pharmaceuticals. Primary endpoint: Annualized bleeding rate during fitusiran efficacy period. Planned start Mar 2018; status: withdrawn.
02
Drugs
fitusiran
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NL-OMON46599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46599.